iSpecimen Q2 2024 GAAP EPS $(0.19) Beats $(0.28) Estimate, Sales $2.864M Miss $2.881M Estimate
Portfolio Pulse from Benzinga Newsdesk
iSpecimen (NASDAQ:ISPC) reported Q2 2024 GAAP EPS of $(0.19), beating the $(0.28) estimate, and sales of $2.864M, missing the $2.881M estimate. EPS improved by 51.28% YoY, and sales increased by 76.25% YoY.
August 06, 2024 | 10:35 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
iSpecimen (NASDAQ:ISPC) reported Q2 2024 GAAP EPS of $(0.19), beating the $(0.28) estimate, and sales of $2.864M, missing the $2.881M estimate. EPS improved by 51.28% YoY, and sales increased by 76.25% YoY.
The better-than-expected EPS and significant YoY improvement in both EPS and sales are positive indicators for ISPC. Despite the slight miss in sales estimates, the overall financial performance suggests a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100